167 related articles for article (PubMed ID: 23052636)
41. Pre-transplant immune state defined by serum markers and alloreactivity predicts acute rejection after living donor kidney transplantation.
Vondran FW; Timrott K; Kollrich S; Steinhoff AK; Kaltenborn A; Schrem H; Klempnauer J; Lehner F; Schwinzer R
Clin Transplant; 2014 Sep; 28(9):968-79. PubMed ID: 24931031
[TBL] [Abstract][Full Text] [Related]
42. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies.
Vaidya S; Partlow D; Barnes T; Gugliuzza K
Transplantation; 2006 Dec; 82(12):1606-9. PubMed ID: 17198244
[TBL] [Abstract][Full Text] [Related]
43. [Evaluation of immune status of kidney transplant recipients by combined HLA-G5 and sCD30].
JIN ZK; TIAN PX; XUE WJ; DING XM; PAN XM; DING CG; JIA LN; GE GQ; HAO JJ
Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(36):2528-31. PubMed ID: 21092456
[TBL] [Abstract][Full Text] [Related]
44. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
Altermann W; Schlaf G; Rothhoff A; Seliger B
Nephrol Dial Transplant; 2007 Oct; 22(10):2795-9. PubMed ID: 17616534
[TBL] [Abstract][Full Text] [Related]
45. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection.
Nafar M; Farrokhi F; Vaezi M; Entezari AE; Pour-Reza-Gholi F; Firoozan A; Eniollahi B
Int Urol Nephrol; 2009; 41(3):687-93. PubMed ID: 19142743
[TBL] [Abstract][Full Text] [Related]
46. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
[TBL] [Abstract][Full Text] [Related]
47. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols.
Hire K; Hering B; Bansal-Pakala P
Transpl Immunol; 2010 Aug; 23(4):209-14. PubMed ID: 20600901
[TBL] [Abstract][Full Text] [Related]
48. Value of soluble CD30 in liver transplantation.
Fábrega E; Unzueta MG; Cobo M; Casafont F; Amado JA; Romero FP
Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168
[TBL] [Abstract][Full Text] [Related]
49. Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation.
Grenzi PC; Campos ÉF; Silva HT; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-DeLima M
Transpl Immunol; 2015 Mar; 32(2):61-5. PubMed ID: 25698648
[TBL] [Abstract][Full Text] [Related]
50. Soluble CD30, Acute Rejection, and Graft Survival: Pre- and 6-Month Post-Transplant Determinations-When Is the Best Time to Measure?
de Holanda MI; Matuck T; de Carvalho DDBM; Domingues EMFL; Curvo R; Glasberg DS; Santos AMG; Borela ÁM; Pôrto LC
Transplant Proc; 2018 Apr; 50(3):728-736. PubMed ID: 29661425
[TBL] [Abstract][Full Text] [Related]
51. Elevated pretransplantation soluble CD30 is associated with decreased early allograft function after human lung transplantation.
Shah AS; Leffell MS; Lucas D; Zachary AA
Hum Immunol; 2009 Feb; 70(2):101-3. PubMed ID: 19126420
[TBL] [Abstract][Full Text] [Related]
52. Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation.
Bauwens AM; van de Graaf EA; van Ginkel WG; van Kessel DA; Otten HG
J Heart Lung Transplant; 2006 Apr; 25(4):416-9. PubMed ID: 16563971
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of pre transplant T-cell activation status by soluble CD 30 determination.
Abbas K; Muzaffar R; Zafar MN; Mubarak M; Naqvi SA; Rizvi SA
J Pak Med Assoc; 2009 Apr; 59(4):212-5. PubMed ID: 19402280
[TBL] [Abstract][Full Text] [Related]
54. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant.
Domingues EM; Matuck T; Graciano ML; Souza E; Rioja S; Falci MC; Monteiro de Carvalho DB; Porto LC
Clin Transplant; 2010; 24(6):821-9. PubMed ID: 20047612
[TBL] [Abstract][Full Text] [Related]
55. [The relationship between acute rejection and expression of sCD30 for the patients after kidney transplantation].
Yang JL; Hao HJ; Qin B; Bang LQ; Zhang ZH; Xin DQ; Guo YL; Na YQ
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):651-3. PubMed ID: 15932723
[TBL] [Abstract][Full Text] [Related]
56. Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation.
Wang D; Wu G; Chen J; Yu Z; Wu W; Yang S; Tan J
Transpl Immunol; 2012 Jun; 26(4):235-9. PubMed ID: 22446727
[TBL] [Abstract][Full Text] [Related]
57. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
58. sCD30, interleukin-1beta-converting enzyme and anti-Annexin V autoantibodies concentrations in heart transplant recipients.
Zeglen S; Zakliczyński M; Nozyński J; Rogala B; Zembala M
Transpl Immunol; 2006 Nov; 16(3-4):227-31. PubMed ID: 17138058
[TBL] [Abstract][Full Text] [Related]
59. A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation.
Hübel K; Cremer B; Heuser E; von Strandmann EP; Hallek M; Hansen HP
Transpl Immunol; 2010 Aug; 23(4):215-9. PubMed ID: 20620210
[TBL] [Abstract][Full Text] [Related]
60. [Estimation of soluble serum CD30 in the diagnosis of early renal allograft dysfunction].
Trailin AV
Klin Khir; 2009 Oct; (10):44-6. PubMed ID: 20458950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
